Latest Data of InnoCare’s Oncology Pipelines Presented at the 65th Annual Meeting of ASH
BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune... Read more.
New Data for Genentech’s Columvi and Lunsumio Presented at ASH 2023 Support Continued Benefit for People With Lymphoma
– Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas... Read more.
ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma
– 88% of patients with advanced stage classical Hodgkin Lymphoma in trial remained progression free at 24 months – – Investigational regimen that eliminates... Read more.
VINSSEN Co., Ltd. Successfully Supplies Hydrogen Fuel Cell for Industry Project in Singapore
Working with key industry partners to trial hydrogen as a marine fuel Successful factory inspection and delivery of hydrogen fuel cell for maritime auxiliary power... Read more.
FCA-Authorised Digital Asset Derivatives Venue GFO-X Raises $30m Series B Funding, Led by M&G Investments
M&G Investments is the £332 billion asset management arm of M&G plc Global Futures and Options Ltd (GFO-X), through its strategic partnership with LCH SA,... Read more.
Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease
– Trial met its primary endpoint across all dose cohorts with 74% of patients at the 0.3 mg/kg dose achieving a complete or partial response within the first... Read more.
Morrow Sodali Acquires Australian Corporate Communication Consultancy, Domestique
Leading Global Stakeholder Engagement Advisory Firm Expands APAC Business, Advancing Strategy in Partnership with TPG SYDNEY–(BUSINESS WIRE)–Morrow Sodali... Read more.
Be Bio Announces New Preclinical Data Demonstrating its Novel Engineered B Cell Medicine (BCM), BE-101, Produces Active and Sustained Levels of Factor IX for the Treatment of Hemophilia B
BE-101 is Company’s Lead Program in Hemophilia B; IND Filing Anticipated in Mid-2024 Be Bio Appoints Glenn Pierce, M.D., Ph.D., Hemophilia Physician-Researcher... Read more.
Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
Updated data from studies of beti-cel in 63 patients with transfusion-dependent beta-thalassemia showed sustained transfusion independence and improvements in iron... Read more.
NKLA DEADLINE TUESDAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Nikola Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – NKLA
NEW YORK–(BUSINESS WIRE)–WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nikola Corporation (NASDAQ: NKLA)... Read more.